Key Metrics of Personalis Inc.
Revenue$73.5M▲ 13.0% YoYFY 2023
Operating income−$110M▲ 4.8% YoY
Net profit−$108M▲ 4.4% YoY
Shareholders' equity$129M
Market cap$1.7BPSNL · $15.93
Competitors10identified
About Personalis Inc.
Sectors
Company details
- Founded
- 2019
- Listed
- Nasdaq: PSNL (since 2019)
Operational Areas of Personalis Inc.
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal namePersonalis Inc.
TickerPSNL
ExchangeNasdaq
CountryUnited States
SEC CIK0001527753
Listed since2019
IndustryMedical Specialities
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Website—
US market & SEC filings
PSNL · Nasdaq · SEC CIK 0001527753
Last price · 31 Oct 2026
$15.93
−0.47%
Market cap$1.7B
P/E—On FY 2023 diluted EPS
Volume749,266
SectorHealth CareMedical Specialities
Country · IPOUnited StatesListed 2019
PSNL share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Personalis Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | hcahealthcare.com | 2011 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.